A new cancer drug called trastuzumab deruxtecan, also known as Enhertu, has just been approved in the UK. This drug is designed to help adults with certain types of advanced cancer that cannot be ...

Enhertu’s drug antibody ratio and bystander effect make it a promising drug for cancers with low or heterogenous HER2 expression.

TOKYO& BASKING RIDGE, N.J.---- Daiichi Sankyo and AstraZeneca have been awarded The Galien Foundation 2024 Prix Galien USA Award for Best Biotechnology Product for ENHERTU ®. ENHERTU is a ...

Enhertu is an antibody-drug conjugate. Here’s how it treats HER2-positive and HER2-low breast cancer.

New data could make HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the first time.

Learn the difference between chemotherapy and immunotherapy and which type of therapy Enhertu is. Discover how it works and how it's given.

Learn about side effects, price, uses, and more of Enhertu (fam-trastuzumab deruxtecan-nxki). It's a prescription drug that treats certain cancers in adults.

At ASCO, Astra Zeneca reported that its drug Enhertu stalled the growth of tumors by more than a year in women with the most common form of metastatic breast cancer.

The overall survival demonstrated by Enhertu in these patients is a significant step forward in the potential to advance current standards of care and offer new options for patients with ...

The approval was based on data from a phase 3 trial that included adults with unresectable or metastatic HER2-low breast cancer who had previous lines of chemotherapy.